Based on these biological effects, the tofersen eligibility has been expanded for an early access program to all people with SOD1-ALS, in countries where such programs are permitted by local regulations and access may be secured (https://www.biogen.com/science-and-innovation/access-programs.html, accessed on 22 April 2023). Here, SOD1 is linked to amyotrophic lateral sclerosis.